High-risk myelodysplastic syndromes in hypomethylants failure

被引:0
作者
Gardin, Claude [1 ,2 ]
机构
[1] Hop Avicenne, Serv Hematol Clin, Bobigny, France
[2] Univ Paris 13, Villetaneuse, France
来源
HEMATOLOGIE | 2010年 / 16卷
关键词
D O I
10.1684/hma.2010.0448
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
引用
收藏
页码:24 / 28
页数:5
相关论文
共 8 条
[1]   Discovery and development of clofarabine: a nucleoside analogue for treating cancer [J].
Bonate, Peter L. ;
Arthaud, Larry ;
Cantrell, William R., Jr. ;
Stephenson, Katherine ;
Secrist, John A., III ;
Weitman, Steve .
NATURE REVIEWS DRUG DISCOVERY, 2006, 5 (10) :855-U2
[2]  
Faderl, 2009, BLOOD, V114, P118, DOI [10.1182/blood.V114.22.118.118, DOI 10.1182/BLOOD.V114.22.118.118]
[3]   Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study [J].
Fenaux, Pierre ;
Mufti, Ghulam J. ;
Hellstrom-Lindberg, Eva ;
Santini, Valeria ;
Finelli, Carlo ;
Giagounidis, Aristoteles ;
Schoch, Robert ;
Gattermann, Norbert ;
Sanz, Guillermo ;
List, Alan ;
Gore, Steven D. ;
Seymour, John F. ;
Bennett, John M. ;
Byrd, John ;
Backstrom, Jay ;
Zimmerman, Linda ;
McKenzie, David ;
Beach, C. L. ;
Silverman, Lewis R. .
LANCET ONCOLOGY, 2009, 10 (03) :223-232
[4]  
Itzykson R, 2009, BLOOD, V114, P3820
[5]  
JABBOUR E, 2008, BLOOD, V112, P1659
[6]  
Ravandi F, 2008, BLOOD, V112, P285
[7]   Defining prior therapy in myelodysplastic syndromes and criteria for relapsed and refractory disease: implications for clinical trial design and enrollment [J].
Sekeres, Mikkael A. ;
Steensma, David P. .
BLOOD, 2009, 114 (13) :2575-2580
[8]   Relationship of Treatment-Related Cytopenias and Response to Lenalidomide in Patients With Lower-Risk Myelodysplastic Syndromes [J].
Sekeres, Mikkael A. ;
Maciejewski, Jaroslaw P. ;
Giagounidis, Aristotle A. N. ;
Wride, Kenton ;
Knight, Robert ;
Raza, Azra ;
List, Alan F. .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (36) :5943-5949